AG
PDLI

Aperio Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Aperio Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$302K Sell
122,095
-905
-0.7% -$2.2K ﹤0.01% 2185
2020
Q3 		$387K Buy
123,000
+19,855
+19% +$63.4K ﹤0.01% 1958
2020
Q2 		$300K Buy
103,145
+5,895
+6% +$18.6K ﹤0.01% 2026
2020
Q1 		$274K Buy
97,250
+27,670
+40% +$89.2K ﹤0.01% 1963
2019
Q4 		$226K Sell
69,580
-589
-0.8% -$1.71K ﹤0.01% 2166
2019
Q3 		$152K Sell
70,169
-13,620
-16% -$36.4K ﹤0.01% 2206
2019
Q2 		$263K Sell
83,789
-1,247
-1% -$4.04K ﹤0.01% 2074
2019
Q1 		$316K Buy
85,036
+18,780
+28% +$63.4K ﹤0.01% 1975
2018
Q4 		$192K Sell
66,256
-46,265
-41% -$127K ﹤0.01% 2143
2018
Q3 		$296K Sell
112,521
-110,796
-50% -$272K ﹤0.01% 2020
2018
Q2 		$523K Sell
223,317
-55,181
-20% -$154K ﹤0.01% 1724
2018
Q1 		$819K Buy
278,498
+10,857
+4% +$29.6K ﹤0.01% 1435
2017
Q4 		$733K Buy
267,641
+50,810
+23% +$156K ﹤0.01% 1501
2017
Q3 		$735K Buy
216,831
+695
+0.3% +$1.93K ﹤0.01% 1456
2017
Q2 		$534K Sell
216,136
-128,935
-37% -$297K ﹤0.01% 1616
2017
Q1 		$783K Buy
345,071
+48,413
+16% +$107K 0.01% 1280
2016
Q4 		$629K Sell
296,658
-64,141
-18% -$179K ﹤0.01% 1374
2016
Q3 		$1.21M Buy
360,799
+33,037
+10% +$105K 0.01% 1019
2016
Q2 		$1.03M Sell
327,762
-163,271
-33% -$544K 0.01% 1059
2016
Q1 		$1.64M Buy
491,033
+266,173
+118% +$830K 0.01% 856
2015
Q4 		$796K Sell
224,860
-379,937
-63% -$1.59M 0.01% 1111
2015
Q3 		$3.04M Sell
604,797
-391,451
-39% -$2.24M 0.03% 594
2015
Q2 		$6.41M Buy
996,248
+305,759
+44% +$2.05M 0.07% 343
2015
Q1 		$4.86M Buy
690,489
+500,064
+263% +$3.62M 0.05% 412
2014
Q4 		$1.47M Sell
190,425
-214,785
-53% -$1.7M 0.02% 741
2014
Q3 		$3.03M Buy
405,210
+324,126
+400% +$3.01M 0.04% 494
2014
Q2 		$785K Buy
81,084
+20,510
+34% +$183K 0.01% 937
2014
Q1 		$503K Buy
+60,574
New +$519K 0.01% 1326
2013
Q4 		– Sell
-70,418
Closed -$593K – 1189
2013
Q3 		$561K Buy
70,418
+26,053
+59% +$209K 0.01% 1093
2013
Q2 		$342K Buy
+44,365
New +$346K 0.01% 1199

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Aperio Group's PDLI Position: Q4 2020 in Review

Aperio Group reduced its PDL BioPharma, Inc. (PDLI) stake by 0.74% in Q4 2020, selling an estimated $2.2K and leaving 122,095 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Aperio Group first reported a position in PDLI in Q2 2013 and has held it in 30 quarters since. The position peaked at $6.41M in Q2 2015. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Aperio Group held 122,095 shares of PDL BioPharma, Inc. worth $302K as of Q4 2020.
  • Aperio Group sold 905 PDL BioPharma, Inc. shares in Q4 2020, an estimated $2.2K.
  • PDL BioPharma, Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2185 holding.
  • Aperio Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 30 quarters since.
  • Aperio Group's PDL BioPharma, Inc. position peaked at $6.41M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.